3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Gemcitabine
9
pembrolizumab
7
Irinotecan
5
Docetaxel
4
Cisplatin
4
Carboplatin
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
Paclitaxel
3
Oxaliplatin
3
Leucovorin
3
Cyclophosphamide
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
pazopanib
2
palbociclib
2
liposomal doxorubicin
2
entrectinib
2
alectinib
2
Vinorelbine
2
Trastuzumab
2
Taxes
2
Radiosurgery
2
Oncolytic Virotherapy
2
Observation
2
Ipilimumab
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Erlotinib Hydrochloride
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Interleukin-15
×
Sarcoma
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled